Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

PURPOSE: The Wee1 kinase inhibitor adavosertib abrogates cell cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase 2 dose (RPh2D). Here, we report results for once-daily adavosertib. PATIENTS AND METHODS...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Cancer Res
Κύριοι συγγραφείς: Takebe, Naoko, Naqash, Abdul Rafeh, Coyne, Geraldine O’Sullivan, Kummar, Shivaani, Do, Khanh, Bruns, Ashley, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Piekarz, Richard, Sharon, Elad, Streicher, Howard, Mittra, Arjun, Miller, Sarah B., Ji, Jiuping, Wilsker, Deborah, Kinders, Robert J., Parchment, Ralph E., Chen, Li, Chang, Ting-Chia, Das, Biswajit, Mugundu, Ganesh, Doroshow, James H., Chen, Alice P.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2021
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282703/
https://ncbi.nlm.nih.gov/pubmed/33863809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-21-0329
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια